SEC Form 4 · accession 0001562180-18-001897
G1 Therapeutics, Inc. · GTHX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark A. Velleca
Officer — President and CEO · Director
Period of report
Apr 16, 2018
Accepted (ET)
Apr 17, 2018 · 12:20 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001560241
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 16, 2018 | M | 7,500 | $3.72 | A | 7,500 | D | |
| Common StockF2 | Apr 16, 2018 | S | 7,000 | $35.9452 | D | 500 | D | |
| Common Stock | Apr 16, 2018 | S | 500 | $36.71 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (Right to Buy)F3 | $3.72 | Apr 16, 2018 | M | 7,500 | D | — | Dec 21, 2025 | Common Stock | 7,500 | 151,933 | D |
Explanation of responses
- F1The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan.
- F2The price represents the weighted average price with a low of $35.62 and a high of $36.45.
- F3The shares underlying this option vested as to 25% of the shares on December 21, 2016, with the remainder vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service through each applicable vesting date.